ArticleFrontiers in immunology2026
Screening and validation of ZFYVE27 as a potential diagnostic biomarker for osteoporosis via integrative bioinformatics and machine learning approaches.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Osteoporosis (OP) is a systemic metabolic skeletal disorder characterized by diminished bone mineral density, deteriorated bone microarchitecture, and a consequently heightened susceptibility to fragility fractures. Bioinformatics approaches serve as a crucial bridge between genomic investigations and clinical translation, and have been extensively utilized in OP research. Nevertheless, the precise identification of core pathogenic genes and the subsequent development of robust and accurate diagnostic biomarkers remain urgent clinical imperatives. Methods: Initially, we identified differentially expressed genes (DEGs) by comparing transcriptomic profiles between healthy controls and osteoporotic patients, followed by functional enrichment analyses of associated biological processes and signaling pathways. Weighted gene co-expression network analysis was subsequently applied to isolate disease-specific module genes. By intersecting these module genes with the DEGs, OP-related DEGs were precisely delineated. The LASSO regression algorithm was utilized to filter seven hub candidate genes. Subsequently, Support Vector Machine and Random Forest machine learning algorithms were employed to further optimize and cross-validate these potential diagnostic biomarkers. The intersection of these multi-algorithmic outputs ultimately designated the core biomarker. Furthermore, an ovariectomized (OVX) mouse model of OP was established to experimentally validate ZFYVE27 expression levels. A competitive endogenous RNA regulatory network was concurrently constructed to elucidate its post-transcriptional regulatory mechanisms underlying OP pathogenesis. Results: ZFYVE27 emerged and was successfully validated as an optimal diagnostic biomarker for OP. Compared to the sham-operated group, both mRNA and protein expression levels of ZFYVE27 were significantly upregulated in the OVX model group ( Conclusion: The present study identifies ZFYVE27 as a novel biomarker for the clinical diagnosis of OP. Furthermore, our findings provide a solid theoretical foundation for further elucidating the molecular pathogenesis of OP and developing targeted therapeutic interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.